Y a-t-il un risque d'infection avec les métastases ?
Oui, les métastases peuvent augmenter le risque d'infections en compromettant le système lymphatique.
InfectionSystème lymphatiqueMétastase
Facteurs de risque
5
#1
Quels cancers sont plus susceptibles de métastaser par voie lymphatique ?
Les cancers du sein, du poumon et de la peau sont souvent associés à des métastases lymphatiques.
Cancer du seinCancer du poumonMétastase
#2
Le tabagisme est-il un facteur de risque ?
Oui, le tabagisme augmente le risque de plusieurs cancers, favorisant les métastases.
TabagismeFacteurs de risqueCancer
#3
L'âge influence-t-il le risque de métastases ?
Oui, le risque de métastases augmente avec l'âge en raison de la diminution de l'immunité.
ÂgeRisque de métastasesImmunité
#4
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux de cancer augmentent le risque de développer des métastases.
Antécédents familiauxRisque de cancerMétastase
#5
L'obésité est-elle un facteur de risque pour les métastases ?
Oui, l'obésité est associée à un risque accru de plusieurs cancers et de métastases.
ObésitéFacteurs de risqueMétastase
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Métastase lymphatique : Questions médicales les plus fréquentes",
"headline": "Métastase lymphatique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Métastase lymphatique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-28",
"dateModified": "2025-02-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Métastase lymphatique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Métastase tumorale",
"url": "https://questionsmedicales.fr/mesh/D009362",
"about": {
"@type": "MedicalCondition",
"name": "Métastase tumorale",
"code": {
"@type": "MedicalCode",
"code": "D009362",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Métastase lymphatique",
"alternateName": "Lymphatic Metastasis",
"code": {
"@type": "MedicalCode",
"code": "D008207",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yanshi Li",
"url": "https://questionsmedicales.fr/author/Yanshi%20Li",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tao Lu",
"url": "https://questionsmedicales.fr/author/Tao%20Lu",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Guohua Hu",
"url": "https://questionsmedicales.fr/author/Guohua%20Hu",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tianxin Lin",
"url": "https://questionsmedicales.fr/author/Tianxin%20Lin",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. Electronic address: lintx@mail.sysu.edu.cn."
}
},
{
"@type": "Person",
"name": "Changhao Chen",
"url": "https://questionsmedicales.fr/author/Changhao%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Radiomics model based on features of axillary lymphatic nodes to predict axillary lymphatic node metastasis in breast cancer.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35869750",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mp.15873"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cancer-associated fibroblast-derived PAI-1 promotes lymphatic metastasis via the induction of EndoMT in lymphatic endothelial cells.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37415190",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13046-023-02714-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "CRIP1 Reshapes the Gastric Cancer Microenvironment to Facilitate Development of Lymphatic Metastasis.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37409440",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/advs.202303246"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cellular Senescence as a Brake or Accelerator for Oncogenic Transformation and Role in Lymphatic Metastasis.",
"datePublished": "2023-02-02",
"url": "https://questionsmedicales.fr/article/36769195",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24032877"
}
},
{
"@type": "ScholarlyArticle",
"name": "Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis.",
"datePublished": "2023-08-10",
"url": "https://questionsmedicales.fr/article/37573226",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.it.2023.07.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Processus néoplasiques",
"item": "https://questionsmedicales.fr/mesh/D009385"
},
{
"@type": "ListItem",
"position": 5,
"name": "Métastase tumorale",
"item": "https://questionsmedicales.fr/mesh/D009362"
},
{
"@type": "ListItem",
"position": 6,
"name": "Métastase lymphatique",
"item": "https://questionsmedicales.fr/mesh/D008207"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Métastase lymphatique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Métastase lymphatique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-28",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Métastase lymphatique",
"description": "Comment diagnostiquer une métastase lymphatique ?\nQuels tests sont utilisés pour détecter des métastases ?\nQuels signes indiquent une métastase lymphatique ?\nPeut-on détecter des métastases par analyse sanguine ?\nQuel rôle joue l'imagerie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D008207#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Métastase lymphatique",
"description": "Quels sont les symptômes des métastases lymphatiques ?\nLes métastases lymphatiques causent-elles des douleurs ?\nPeut-on avoir des symptômes sans métastases visibles ?\nLes symptômes varient-ils selon le type de cancer ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D008207#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Métastase lymphatique",
"description": "Peut-on prévenir les métastases lymphatiques ?\nQuels facteurs de risque augmentent les métastases ?\nL'alimentation influence-t-elle le risque de métastases ?\nLe dépistage régulier est-il important ?\nLes vaccinations peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D008207#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Métastase lymphatique",
"description": "Quels traitements sont disponibles pour les métastases lymphatiques ?\nLa radiothérapie est-elle efficace contre les métastases ?\nQuand la chirurgie est-elle recommandée ?\nQuels médicaments sont utilisés pour traiter les métastases ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D008207#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Métastase lymphatique",
"description": "Quelles complications peuvent survenir avec les métastases ?\nLes métastases lymphatiques affectent-elles la fonction immunitaire ?\nComment les métastases impactent-elles la qualité de vie ?\nLes métastases peuvent-elles causer des problèmes respiratoires ?\nY a-t-il un risque d'infection avec les métastases ?",
"url": "https://questionsmedicales.fr/mesh/D008207#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Métastase lymphatique",
"description": "Quels cancers sont plus susceptibles de métastaser par voie lymphatique ?\nLe tabagisme est-il un facteur de risque ?\nL'âge influence-t-il le risque de métastases ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'obésité est-elle un facteur de risque pour les métastases ?",
"url": "https://questionsmedicales.fr/mesh/D008207#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une métastase lymphatique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (IRM, TDM) et biopsie des ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter des métastases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'échographie, la tomographie et la scintigraphie lymphatique."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une métastase lymphatique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un gonflement des ganglions lymphatiques et des douleurs localisées peuvent indiquer des métastases."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des métastases par analyse sanguine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analyses sanguines peuvent révéler des marqueurs tumoraux, mais ne suffisent pas pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie permet de visualiser l'étendue des métastases et d'évaluer les ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes des métastases lymphatiques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des ganglions enflés, douleur, fatigue et perte de poids."
}
},
{
"@type": "Question",
"name": "Les métastases lymphatiques causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des douleurs localisées au niveau des ganglions touchés."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans métastases visibles ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes sans métastases détectables par imagerie."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction du type de cancer primaire et de sa localisation."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec la progression de la maladie et l'extension des métastases."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les métastases lymphatiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un dépistage précoce et un traitement efficace des cancers primaires."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque augmentent les métastases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le tabagisme et l'obésité sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de métastases ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut réduire le risque de cancer et donc de métastases lymphatiques."
}
},
{
"@type": "Question",
"name": "Le dépistage régulier est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage régulier permet de détecter les cancers à un stade précoce, réduisant le risque de métastases."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancers associés."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les métastases lymphatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la radiothérapie et la chimiothérapie ciblée."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace contre les métastases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut réduire la taille des métastases et soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est recommandée si les métastases sont localisées et accessibles sans risque majeur."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les métastases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de tyrosine kinase et l'immunothérapie sont utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction du type de cancer et de l'état du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les métastases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obstruction lymphatique, la douleur chronique et l'infection."
}
},
{
"@type": "Question",
"name": "Les métastases lymphatiques affectent-elles la fonction immunitaire ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent compromettre la fonction immunitaire en affectant les ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Comment les métastases impactent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs, une fatigue accrue et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les métastases peuvent-elles causer des problèmes respiratoires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, si elles se propagent aux ganglions lymphatiques thoraciques, cela peut affecter la respiration."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infection avec les métastases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les métastases peuvent augmenter le risque d'infections en compromettant le système lymphatique."
}
},
{
"@type": "Question",
"name": "Quels cancers sont plus susceptibles de métastaser par voie lymphatique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du sein, du poumon et de la peau sont souvent associés à des métastases lymphatiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de plusieurs cancers, favorisant les métastases."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de métastases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de métastases augmente avec l'âge en raison de la diminution de l'immunité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer augmentent le risque de développer des métastases."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque pour les métastases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à un risque accru de plusieurs cancers et de métastases."
}
}
]
}
]
}
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. Electronic address: lintx@mail.sysu.edu.cn.
Department of Urology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, State Key Laboratory of Oncology in South China, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
California Pacific Medical Center and Research Institute, University of California School of Medicine, San Francisco, USA. Stanley.Leong@sutterhealth.org.
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, State Key Laboratory of Oncology in South China, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Department of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Department of Urology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, State Key Laboratory of Oncology in South China, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) Cancer Center, MGH and Harvard Medical School (HMS), Boston, MA 02114, USA.
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) Cancer Center, MGH and Harvard Medical School (HMS), Boston, MA 02114, USA.
Breast cancer (BC) is among the most common cancers worldwide. Machine learning-based radiomics model could predict axillary lymph node metastasis (ALNM) of BC accurately....
The purpose is to develop a machine learning model to predict ALNM of BC by focusing on the radiomics features of axillary lymphatic node (ALN)....
A group of 398 BC patients with 800 ALNs were retrospectively collected. A set of patient characteristics were obtained to form clinical factors. Three hundred and twenty-six radiomics features were e...
Among the 800 cases of ALNs, there were 388 cases of positive metastasis (48.50%) and 412 cases of negative metastasis (51.50%). The baseline clinical model achieved the performance with an AUC = 0.89...
Combinations of feature selection methods and machine learning-based classification algorithms can develop promising predictive models to predict ALNM in BC using CECT features. The combined model of ...
Endothelial-mesenchymal transition (EndoMT) is an emerging adaptive process that modulates lymphatic endothelial function to drive aberrant lymphatic vascularization in the tumour microenvironment (TM...
Immunofluorescent staining of α-SMA, LYVE-1 and DAPI were examined in primary tumour samples obtained from 57 CSCC patients. Assessment of cytokines secreted by CAFs and normal fibroblasts (NFs) was p...
CAF-derived PAI-1 promoted the EndoMT of LECs in CSCC. LECs undergoing EndoMT could initiate tumour neolymphangiogenesis that facilitated cancer cell intravasation/extravasation, which in turn promote...
Our data indicate that CAF-derived PAI-1 acts as an important neolymphangiogenesis-initiating molecular during CSCC progression through modulating the EndoMT of LECs, resulting in promotion of metasta...
Lymphangiogenesis in tumors provides an auxiliary route for cancer cell invasion to drainage lymph nodes, facilitating the development of lymphatic metastasis (LM). However, the mechanisms governing t...
Cellular senescence-the irreversible cell cycle arrest driven by a variety of mechanisms and, more specifically, the senescence-associated secretory phenotype (SASP)-is an important area of research i...
The natural history of advanced malignant melanoma demonstrates that, in most cases, widespread tumor dissemination is preceded by regional metastases involving tumor-draining lymph nodes [sentinel ly...
Gastric cancer (GC) is a malignant tumor with a high mortality rate, and lymphatic metastasis is the main mode of GC metastasis. The nuclear transcriptional regulatory protein SATB1 has been confirmed...
Epithelial-mesenchymal transition (EMT) is known as the pivotal process of GC metastasis. To evaluate the relationship between SATB1 and EMT in GC metastasis, the immunohistochemical method was used t...
Abnormal positive expression of SATB1 protein in paraffin-embedded tumor tissues was positively correlated with local invasion, lymph node metastasis, and TNM staging in gastric cancer. There was a st...
The GC patients with overexpression of SATB1 tended to have advanced stage and lymph node metastasis. SATB1 was positively correlated with EMT in Gastric Cancer....
Liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin) plays an important regulatory role in a variety of diseases, including tumors. However, the underlying mechanism of LSECtin in ...
This study aims to predict the lymphatic metastasis in Ewing's sarcoma (ES) patients by nomogram. The risk of lymphatic metastasis in patients with ES was predicted by the built model, which provided ...
A total of 929 patients diagnosed with ES were enrolled from the year of 2010 to 2016 in the Surveillance, Epidemiology, and End Results (SEER) database. The nomogram was established to determine pred...
In this study, the nomogram was established based on six significant factors (survival time, race, T stage, M stage, surgery, and lung metastasis), which were identified for lymphatic metastasis in ES...
In this study, we constructed and developed a nomogram with risk factors to predict lymphatic metastasis in ES patients and validated accuracy of itself. We found T stage (Tx OR = 2.540, 95%CI = 1.433...
The design of nanomedicine for cancer therapy, especially the treatment of tumor metastasis has received great attention. Proteasome inhibition is accepted as a new strategy for cancer therapy. Despit...
Lymphatic metastasis (LM) emerges as an independent prognostic marker for hypopharyngeal squamous cell carcinoma (HSPSCC), chiefly contributing to treatment inefficacy. This study aimed to scrutinize ...
In a preceding investigation, HSP90AA1, a differential gene, was discovered through transcriptome sequencing of HPSCC tissues, considering both the presence and absence of LM. Validation of HSP90AA1 e...
HSP90AA1 is substantially up-regulated in HPSCC with LM and is identified as an independent prognostic risk determinant. The down-regulation of HSP90AA1 can achieve inhibition of tumor cell proliferat...
HSP90AA1, by controlling EMT, can foster LM in HPSCC.This finding sets the foundation for delving into new therapeutic targets for HPSCC....